share_log

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $1.5

Benzinga Real-time News ·  Jan 18, 2023 22:41

Lake Street analyst Frank Takkinen maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $5 to $1.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment